Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

505 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. Among authors: popovic v. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.
HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial.
Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, Creticos C, Orozco-Cronin P, Popovic V, Mastro TD; VISION/VAX004 Study Team. Bartholow BN, et al. Among authors: popovic v. J Acquir Immune Defic Syndr. 2005 May 1;39(1):90-101. doi: 10.1097/01.qai.0000143600.41363.78. J Acquir Immune Defic Syndr. 2005. PMID: 15851919 Clinical Trial.
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. Gilbert PB, et al. Among authors: popovic v. J Infect Dis. 2005 Sep 15;192(6):974-83. doi: 10.1086/432734. Epub 2005 Aug 12. J Infect Dis. 2005. PMID: 16107949 Clinical Trial.
Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials.
Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, Hirsch A, Ippolito T, Luck A, Longhi M, Gulati V, Winslow N, Gurwith M, Sinangil F, Berman PW. Francis DP, et al. Among authors: popovic v. AIDS. 2003 Jan 24;17(2):147-56. doi: 10.1097/01.aids.0000050786.28043.62. AIDS. 2003. PMID: 12545073 Review. No abstract available.
PreHevbrio: the first approved 3-antigen hepatitis B vaccine.
Vesikari T, Langley JM, Popovic V, Diaz-Mitoma F. Vesikari T, et al. Among authors: popovic v. Expert Rev Vaccines. 2023 Jan-Dec;22(1):1041-1054. doi: 10.1080/14760584.2023.2274482. Epub 2023 Nov 6. Expert Rev Vaccines. 2023. PMID: 37877189 Free article. Review.
Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.
Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, Strasburger C, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF. Giustina A, et al. Among authors: popovic v. Pituitary. 2023 Oct;26(5):583-596. doi: 10.1007/s11102-023-01345-0. Epub 2023 Aug 28. Pituitary. 2023. PMID: 37640885 Free PMC article.
505 results